Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


GREY:VIVXF - Post by User

Bullboard Posts
Post by Bullboards_Sealon Mar 27, 2012 10:28am
375 Views
Post# 19722407

NR - Avivagen Presents Canine Supplement at PEI Ho

NR - Avivagen Presents Canine Supplement at PEI Ho

Avivagen Presents Canine Supplement at PEI Home Show

OTTAWA, ONTARIO, March 27, 2012 - Avivagen Animal Health Inc., the wholly-owned commercial arm of Chemaphor Inc. (TSX Venture Exchange: CFR), exhibited at the 2012 PEI Provincial Home Show, the largest consumer trade show on Prince Edward Island on March 9-11. The event drew 11,900 attendees.

The Avivagen team discussed the benefits of Oximunol(TM) Chewables with many interested dog owners and sampled over 500 Oximunol Chewables to eager and excited dog owners. Attendees at the show ranged from pet parents to owners of Boarding and Doggie Daycare facilities, groomers, breeders and agility competitors.

Dr. Jamie Nickerson, Avivagen's Director of Biology in Charlottetown, considered the event a great success. "For me, it was a fantastic opportunity to personally meet with dog owners and highlighted the fact that there is a genuine need for our product in the segment of natural animal health.", said Nickerson. "Dog owners were very excited to hear that one small tablet can offer so many different benefits to their dog. It was a gratifying experience and I am already looking forward to next year's show."

"We found one thing that interested people at our booth was the need for less vacuuming at home due to improved skin and coat health of dogs on Oximunol", said Ashley Craswell, Atlantic Sales Representative. "Once we mentioned that Oximunol assists the natural immune system and as a result has a positive impact on mobility and allows greater walk enjoyment and overall general health for their dogs, people were very eager to take Oximunol home with them to try it out with their own dog." Avivagen staff are following up via email, phone, Facebook and Twitter on the progress of the 500+ PEI dogs currently sampling Oximunol(TM) Chewables.

About Avivagen

Avivagen, a wholly-owned subsidiary of Chemaphor, is dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials. More information can be found at www.avivagen.com.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

David Hankinson Graham Burton, PhD

CEO, Chemaphor Inc. President and Co-Founder, Chemaphor Inc.

Phone: 902-825-9270 Phone: 613-990-0969

d.hankinson@chemaphor.com g.burton@chemaphor.com

Copyright (c) 2012 Thenewswire.ca - All rights reserved.

Bullboard Posts